Zenas Biopharma (ZBIO) closed at $27.75 on November 17, 2026, down 0.6% from the previous close, on volume of 421,993 shares (30-day average 490,831).
Data as of November 17, 2026.
Globe Newswire (Tue, 17-Nov 7:00 AM ET)
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Zenas BioPharma highlights new-hire equity incentives with 74,900 RSUs tied to four-year retention
Market Chameleon (Mon, 19-Oct 7:37 AM ET)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Oct 4:15 PM ET)
Globe Newswire (Mon, 12-Oct 7:00 AM ET)
Globe Newswire (Wed, 7-Oct 7:05 AM ET)
Zenas BioPharma to Host Virtual R&D Event
Globe Newswire (Tue, 6-Oct 7:05 AM ET)
Globe Newswire (Tue, 22-Sep 7:05 AM ET)
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Globe Newswire (Tue, 8-Sep 7:05 AM ET)
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.
As of November 18, 2026, ZBIO stock price climbed to $28.04 with 61,210 million shares trading.
ZBIO has a beta of 0.02, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.00 to the broad based SPY ETF.
ZBIO has a market cap of $1.83 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ZBIO has underperformed the market in the last year with a return of -21.9%, while the SPY ETF gained +10.7%. In the last 3 month period, ZBIO fell short of the market, returning -8.1%, while SPY returned -5.4%. However, in the most recent 2 weeks ZBIO has outperformed the stock market by returning -1.2%, while SPY returned -3.4%.
ZBIO support price is $26.68 and resistance is $28.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.